Rainald Knecht

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy

Jan B. Vermorken, José Trigo, Ricardo Hitt et al. · Journal of Clinical Oncology · 2007 · 996 citations · Full text

Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells

Birgit Spänkuch-Schmitt, Georg Wolf, Christine Solbach et al. · Oncogene · 2002 · 148 citations

Medicine, Receptor Tyrosine Kinase, Antisense Therapy +8

Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo

Juping Yuan, Andrea Krämer, Yves Matthess et al. · Oncogene · 2005 · 130 citations

Medicine, Cyclin B1, Stable Gene Silencing +8

Cancer Inhibition in Nude Mice After Systemic Application of U6 Promoter-Driven Short Hairpin RNAs Against PLK1

B. Spankuch, Y. Matthess, Rainald Knecht et al. · JNCI Journal of the National Cancer Institute · 2004 · 114 citations · Full text

Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study

José Trigo, Ricardo Hitt, P. Koralewski et al. · Journal of Clinical Oncology · 2004 · 108 citations

Pathology, Phase Ii Study, Cetuximab Monotherapy +16